Ⓐ
PeptiBrief
Evidence Library
observational_study · 2013

Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus

Topuz M|Celik A|Aslantas T|Demir AK|Aydin S|Aydin S · Journal of Investigative Medicine
weakDOI · 10.2310/jim.0000000000000003PMID · 24113736Verified
View source
Plain-English summary

Lower adropin levels were associated with worse endothelial function, but this does not prove that giving adropin would improve vascular health.

Population
Adults with type 2 diabetes mellitus
Sample size
92
Intervention
Measurement of plasma adropin and brachial flow-mediated dilation
Outcomes measured
Adropin concentration|Endothelial dysfunction|Glycaemic markers
Key findings
Adropin was positively associated with flow-mediated dilation and independently associated with endothelial dysfunction classification.
Limitations
Observational design|No therapeutic intervention|Single clinical population|Association cannot prove causation
Risk of bias
High — clinically relevant association but substantial confounding and no intervention.
Citation
Topuz M|Celik A|Aslantas T|Demir AK|Aydin S|Aydin S (2013). Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. Journal of Investigative Medicine. https://doi.org/10.2310/jim.0000000000000003
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.